Oxford Biomedica - OXB Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 1,245
  • Forecasted Upside: 194.67%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
GBX 422.50
▼ -5.5 (-1.29%)

This chart shows the closing price for OXB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oxford Biomedica Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OXB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OXB

Analyst Price Target is GBX 1,245
▲ +194.67% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Oxford Biomedica in the last 3 months. The average price target is GBX 1,245, with a high forecast of GBX 1,380 and a low forecast of GBX 1,110. The average price target represents a 194.67% upside from the last price of GBX 422.50.

This chart shows the closing price for OXB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Oxford Biomedica. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/6/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/4/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/2/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/3/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/1/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/28/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/11/2022Royal Bank of CanadaBoost TargetOutperformGBX 1,020 ➝ GBX 1,110
6/30/2022Royal Bank of CanadaReiterated RatingOutperformGBX 1,070
6/21/2022Royal Bank of CanadaReiterated RatingOutperformGBX 1,070
5/23/2022Royal Bank of CanadaReiterated RatingOutperformGBX 1,070
4/20/2022Liberum CapitalReiterated RatingBuyGBX 1,380
3/24/2022Royal Bank of CanadaReiterated RatingOutperformGBX 1,340
2/1/2022Royal Bank of CanadaLower TargetOutperformGBX 1,450 ➝ GBX 1,340
10/19/2021Peel HuntReiterated RatingBuyGBX 2,150
10/19/2021Peel HuntReiterated RatingBuyGBX 2,150
5/19/2021Liberum CapitalBoost TargetBuyGBX 1,300 ➝ GBX 1,330
5/18/2021Peel HuntReiterated RatingBuyGBX 1,150
5/18/2021Peel HuntReiterated RatingBuyGBX 1,150
5/18/2021Numis SecuritiesReiterated RatingBuyGBX 1,200
4/15/2021Liberum CapitalReiterated RatingBuyGBX 1,300 ➝ GBX 1,280
4/6/2021Liberum CapitalReiterated RatingBuyGBX 1,280
8/3/2020Liberum CapitalReiterated RatingBuy
7/31/2020Peel HuntReiterated RatingBuy
7/21/2020Peel HuntReiterated RatingBuy
7/21/2020Liberum CapitalReiterated RatingBuy
7/2/2020Peel HuntReiterated RatingBuy
6/24/2020Liberum CapitalLower TargetBuyGBX 1,090 ➝ GBX 1,050
6/19/2020Peel HuntReiterated RatingBuyGBX 1,050 ➝ GBX 1,000
6/8/2020Peel HuntReiterated RatingBuyGBX 1,060 ➝ GBX 1,050
6/8/2020Liberum CapitalReiterated RatingBuy
6/1/2020Peel HuntReiterated RatingBuy
5/29/2020Liberum CapitalReiterated RatingBuy
5/14/2020Jefferies Financial GroupBoost TargetHoldGBX 700 ➝ GBX 730
5/13/2020Peel HuntReiterated RatingBuy
5/13/2020Liberum CapitalReiterated RatingBuy
5/6/2020Liberum CapitalReiterated RatingBuy
5/1/2020Peel HuntReiterated RatingBuy
4/28/2020Liberum CapitalBoost TargetBuyGBX 860 ➝ GBX 1,090
4/24/2020Peel HuntReiterated RatingBuy
4/8/2020Liberum CapitalReiterated RatingBuy
4/7/2020Peel HuntReiterated RatingBuy
3/18/2020Peel HuntReiterated RatingBuy
3/18/2020Liberum CapitalReiterated RatingBuy
3/5/2020Peel HuntReiterated RatingBuy
2/13/2020Peel HuntReiterated RatingBuy
2/5/2020Peel HuntReiterated RatingBuy
1/29/2020Liberum CapitalReiterated RatingBuy
1/27/2020Peel HuntReiterated RatingBuy
1/13/2020Liberum CapitalBoost TargetBuyGBX 810 ➝ GBX 860
1/10/2020Peel HuntReiterated RatingBuy
12/19/2019Peel HuntReiterated RatingBuy
12/19/2019Liberum CapitalReiterated RatingBuy
12/5/2019Liberum CapitalReiterated RatingBuy
12/5/2019Peel HuntReiterated RatingBuy
11/15/2019Liberum CapitalReiterated RatingBuy
11/4/2019Peel HuntReiterated RatingBuy
10/22/2019Peel HuntReiterated RatingBuy
10/22/2019Liberum CapitalReiterated RatingBuy
9/30/2019Liberum CapitalInitiated CoverageBuyGBX 810
9/2/2019Peel HuntReiterated RatingBuy
8/1/2019Peel HuntReiterated RatingBuy
7/3/2019Peel HuntReiterated RatingBuy
6/26/2019Peel HuntReiterated RatingBuy
6/26/2019Peel HuntReiterated RatingBuy
6/4/2019Peel HuntReiterated RatingBuy
5/14/2019Peel HuntReiterated RatingBuy
5/2/2019Peel HuntReiterated RatingBuy
4/23/2019Peel HuntInitiated CoverageBuy
4/2/2019Peel HuntReiterated RatingBuy
3/12/2019Peel HuntReiterated RatingBuy
1/30/2019Peel HuntReiterated RatingBuy
1/17/2019Peel HuntReiterated RatingBuy
1/7/2019Peel HuntReiterated RatingBuy
12/24/2018Peel HuntReiterated RatingBuy
12/4/2018Peel HuntReiterated RatingBuy
11/23/2018Peel HuntReiterated RatingBuy
11/1/2018Peel HuntReiterated RatingBuy
10/25/2018Peel HuntReiterated RatingBuy
10/3/2018Peel HuntReiterated RatingBuy
9/13/2018Peel HuntReiterated RatingBuy
9/4/2018Peel HuntReiterated RatingBuy
8/28/2018Peel HuntReiterated RatingBuy
8/1/2018Peel HuntReiterated RatingBuy
7/18/2018Peel HuntReiterated RatingBuy
7/3/2018Peel HuntReiterated RatingBuy
6/13/2018Jefferies Financial GroupDowngradeHold
5/31/2018Peel HuntReiterated RatingBuy
5/1/2018Peel HuntReiterated RatingBuyGBX 16
4/19/2018Peel HuntReiterated RatingBuyGBX 16
4/4/2018Peel HuntReiterated RatingBuyGBX 16
3/15/2018Peel HuntBoost TargetBuyGBX 13 ➝ GBX 16
3/1/2018Peel HuntReiterated RatingBuyGBX 13
2/15/2018Peel HuntReiterated RatingBuyGBX 13
2/1/2018Peel HuntReiterated RatingBuyGBX 13
(Data available from 1/29/2018 forward)

News Sentiment Rating

0.93 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/3/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/1/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/1/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/31/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/30/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/30/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/29/2023

Current Sentiment

  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Oxford Biomedica logo
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Read More

Today's Range

Now: GBX 422.50
Low: 411.95
High: 431.96

50 Day Range

MA: GBX 415.71
Low: 357
High: 480.50

52 Week Range

Now: GBX 422.50
Low: 276.62
High: 918

Volume

54,308 shs

Average Volume

96,714 shs

Market Capitalization

£406.71 million

P/E Ratio

2,112.50

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Oxford Biomedica?

The following Wall Street research analysts have issued stock ratings on Oxford Biomedica in the last year: Liberum Capital, and Royal Bank of Canada.
View the latest analyst ratings for OXB.

What is the current price target for Oxford Biomedica?

2 Wall Street analysts have set twelve-month price targets for Oxford Biomedica in the last year. Their average twelve-month price target is GBX 1,245, suggesting a possible upside of 194.7%. Liberum Capital has the highest price target set, predicting OXB will reach GBX 1,380 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of GBX 1,110 for Oxford Biomedica in the next year.
View the latest price targets for OXB.

What is the current consensus analyst rating for Oxford Biomedica?

Oxford Biomedica currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OXB will outperform the market and that investors should add to their positions of Oxford Biomedica.
View the latest ratings for OXB.

What other companies compete with Oxford Biomedica?

How do I contact Oxford Biomedica's investor relations team?

Oxford Biomedica's physical mailing address is Windrush Court, Transport Way, OXFORD, OX4 6LT, United Kingdom. The biopharmaceutical company's listed phone number is +44-1865-783000. The official website for Oxford Biomedica is www.oxfordbiomedica.co.uk. Learn More about contacing Oxford Biomedica investor relations.